Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $370.2 million.

  • Xeris Biopharma Holdings' Liabilities and Shareholders Equity rose 15.29% to $370.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 2.39%. This contributed to the annual value of $323.1 million for FY2024, which is 0.14% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Liabilities and Shareholders Equity stood at $370.2 million, which was up 10.61% from $334.7 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Liabilities and Shareholders Equity high stood at $370.2 million for Q3 2025, and its period low was $131.3 million during Q3 2021.
  • For the 3-year period, Xeris Biopharma Holdings' Liabilities and Shareholders Equity averaged around $330.3 million, with its median value being $327.8 million (2023).
  • In the last 5 years, Xeris Biopharma Holdings' Liabilities and Shareholders Equity surged by 130.85% in 2022 and then fell by 6.36% in 2023.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Liabilities and Shareholders Equity stood at $304.4 million in 2021, then increased by 13.20% to $344.5 million in 2022, then dropped by 6.36% to $322.6 million in 2023, then increased by 0.14% to $323.1 million in 2024, then rose by 15.29% to $370.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $370.2 million for Q3 2025, versus $334.7 million for Q2 2025 and $315.5 million for Q1 2025.